Cargando…

Development of a Novel Prognostic Signature Based on Antigen Processing and Presentation in Patients with Breast Cancer

Background: Complex antigen processing and presentation processes are involved in the development and progression of breast cancer (BC). A single biomarker is unlikely to adequately reflect the complex interplay between immune cells and cancer; however, there have been few attempts to find a robust...

Descripción completa

Detalles Bibliográficos
Autores principales: Qi, Aoshuang, Ju, Mingyi, Liu, Yinfeng, Bi, Jia, Wei, Qian, He, Miao, Wei, Minjie, Zhao, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262234/
https://www.ncbi.nlm.nih.gov/pubmed/34257557
http://dx.doi.org/10.3389/pore.2021.600727
_version_ 1783719151837118464
author Qi, Aoshuang
Ju, Mingyi
Liu, Yinfeng
Bi, Jia
Wei, Qian
He, Miao
Wei, Minjie
Zhao, Lin
author_facet Qi, Aoshuang
Ju, Mingyi
Liu, Yinfeng
Bi, Jia
Wei, Qian
He, Miao
Wei, Minjie
Zhao, Lin
author_sort Qi, Aoshuang
collection PubMed
description Background: Complex antigen processing and presentation processes are involved in the development and progression of breast cancer (BC). A single biomarker is unlikely to adequately reflect the complex interplay between immune cells and cancer; however, there have been few attempts to find a robust antigen processing and presentation-related signature to predict the survival outcome of BC patients with respect to tumor immunology. Therefore, we aimed to develop an accurate gene signature based on immune-related genes for prognosis prediction of BC. Methods: Information on BC patients was obtained from The Cancer Genome Atlas. Gene set enrichment analysis was used to confirm the gene set related to antigen processing and presentation that contributed to BC. Cox proportional regression, multivariate Cox regression, and stratified analysis were used to identify the prognostic power of the gene signature. Differentially expressed mRNAs between high- and low-risk groups were determined by KEGG analysis. Results: A three-gene signature comprising HSPA5 (heat shock protein family A member 5), PSME2 (proteasome activator subunit 2), and HLA-F (major histocompatibility complex, class I, F) was significantly associated with OS. HSPA5 and PSME2 were protective (hazard ratio (HR) < 1), and HLA-F was risky (HR > 1). Risk score, estrogen receptor (ER), progesterone receptor (PR) and PD-L1 were independent prognostic indicators. KIT and ACACB may have important roles in the mechanism by which the gene signature regulates prognosis of BC. Conclusion: The proposed three-gene signature is a promising biomarker for estimating survival outcomes in BC patients.
format Online
Article
Text
id pubmed-8262234
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-82622342021-07-12 Development of a Novel Prognostic Signature Based on Antigen Processing and Presentation in Patients with Breast Cancer Qi, Aoshuang Ju, Mingyi Liu, Yinfeng Bi, Jia Wei, Qian He, Miao Wei, Minjie Zhao, Lin Pathol Oncol Res Society Journal Archive Background: Complex antigen processing and presentation processes are involved in the development and progression of breast cancer (BC). A single biomarker is unlikely to adequately reflect the complex interplay between immune cells and cancer; however, there have been few attempts to find a robust antigen processing and presentation-related signature to predict the survival outcome of BC patients with respect to tumor immunology. Therefore, we aimed to develop an accurate gene signature based on immune-related genes for prognosis prediction of BC. Methods: Information on BC patients was obtained from The Cancer Genome Atlas. Gene set enrichment analysis was used to confirm the gene set related to antigen processing and presentation that contributed to BC. Cox proportional regression, multivariate Cox regression, and stratified analysis were used to identify the prognostic power of the gene signature. Differentially expressed mRNAs between high- and low-risk groups were determined by KEGG analysis. Results: A three-gene signature comprising HSPA5 (heat shock protein family A member 5), PSME2 (proteasome activator subunit 2), and HLA-F (major histocompatibility complex, class I, F) was significantly associated with OS. HSPA5 and PSME2 were protective (hazard ratio (HR) < 1), and HLA-F was risky (HR > 1). Risk score, estrogen receptor (ER), progesterone receptor (PR) and PD-L1 were independent prognostic indicators. KIT and ACACB may have important roles in the mechanism by which the gene signature regulates prognosis of BC. Conclusion: The proposed three-gene signature is a promising biomarker for estimating survival outcomes in BC patients. Frontiers Media S.A. 2021-04-01 /pmc/articles/PMC8262234/ /pubmed/34257557 http://dx.doi.org/10.3389/pore.2021.600727 Text en Copyright © 2021 Qi, Ju, Liu, Bi, Wei, He, Wei and Zhao. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Society Journal Archive
Qi, Aoshuang
Ju, Mingyi
Liu, Yinfeng
Bi, Jia
Wei, Qian
He, Miao
Wei, Minjie
Zhao, Lin
Development of a Novel Prognostic Signature Based on Antigen Processing and Presentation in Patients with Breast Cancer
title Development of a Novel Prognostic Signature Based on Antigen Processing and Presentation in Patients with Breast Cancer
title_full Development of a Novel Prognostic Signature Based on Antigen Processing and Presentation in Patients with Breast Cancer
title_fullStr Development of a Novel Prognostic Signature Based on Antigen Processing and Presentation in Patients with Breast Cancer
title_full_unstemmed Development of a Novel Prognostic Signature Based on Antigen Processing and Presentation in Patients with Breast Cancer
title_short Development of a Novel Prognostic Signature Based on Antigen Processing and Presentation in Patients with Breast Cancer
title_sort development of a novel prognostic signature based on antigen processing and presentation in patients with breast cancer
topic Society Journal Archive
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262234/
https://www.ncbi.nlm.nih.gov/pubmed/34257557
http://dx.doi.org/10.3389/pore.2021.600727
work_keys_str_mv AT qiaoshuang developmentofanovelprognosticsignaturebasedonantigenprocessingandpresentationinpatientswithbreastcancer
AT jumingyi developmentofanovelprognosticsignaturebasedonantigenprocessingandpresentationinpatientswithbreastcancer
AT liuyinfeng developmentofanovelprognosticsignaturebasedonantigenprocessingandpresentationinpatientswithbreastcancer
AT bijia developmentofanovelprognosticsignaturebasedonantigenprocessingandpresentationinpatientswithbreastcancer
AT weiqian developmentofanovelprognosticsignaturebasedonantigenprocessingandpresentationinpatientswithbreastcancer
AT hemiao developmentofanovelprognosticsignaturebasedonantigenprocessingandpresentationinpatientswithbreastcancer
AT weiminjie developmentofanovelprognosticsignaturebasedonantigenprocessingandpresentationinpatientswithbreastcancer
AT zhaolin developmentofanovelprognosticsignaturebasedonantigenprocessingandpresentationinpatientswithbreastcancer